Products & ServicesEvent: September 2, 2026
Sonas Pharma introduced precision changes to alter cannabinoid molecule behavior in the body with LGS as its lead indication.
Published
Signal category
Products & Services
Quote
“We're building on the cannabinoid chemistry I spent those years immersed in, engineering it further — we have introduced precision changes to alter changes how these molecules behave in the body — with LGS as our lead indication.”
— Chris Hayes|Sonas Pharma team
Company
Sonas Pharma
Innovative ECS medicines for the future.
- Industry
- Biotechnology Research
- Location
- Belfast, GB
- Company size
- 2 employees
Developing innovative ECS medicines to treat epilepsy and obesity.